With the robust demand for personalized medicines and the growing adoption of digital technology, the precision medicine ...
Additional data from CheckMate 274 showed that adjuvant nivolumab benefits patients with muscle-invasive bladder cancer with ...
Results from a post-hoc exploratory subgroup analysis from the NIAGARA Phase III trial showed AstraZeneca’s (AZN) IMFINZI, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback